Reversal of multidrug resistance by novel verapamil analogs in cancer cells

Anti-Cancer Drugs

Volumn 9, Issue 2, 1998, Pages 157-165

  Choi, Sang Un ^a   Lee, Chong Ock ^a   Kim, Kwang Hee ^a   Choi, Eun Jung ^a   Park, Sung Hee ^a   Shin, Hwa Sup ^a   Yoo, Sung Eun ^a   Jung, Noh Pal ^b   Lee, Byung Ho ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Cardiac toxicity; KR 30032; KR 30035; Multidrug; P glycoprotein; Resistance

Indexed keywords

GLYCOPROTEIN P; KR 30032; KR 30035; PACLITAXEL; RHODAMINE; TAMOXIFEN; UNCLASSIFIED DRUG; VERAPAMIL; VERAPAMIL DERIVATIVE;

ANIMAL TISSUE; AORTA; ARTERY TONE; ARTICLE; BIOACCUMULATION; CANCER CELL; CARDIOTOXICITY; CYTOTOXICITY; DRUG POTENTIATION; GUINEA PIG; HEART LEFT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031890560     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199802000-00007     Document Type: Article

References (19)

1. Campling BG, Young LC, Beer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997; 3: 115-22.
2. Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a model for multidrug resistance. Nature 1986; 324: 485-9.
3. Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 1993; 13: 88-109.
4. Harker WG, Sikic BI. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res 1986; 46: 2369-73.
5. Tsuruo T, Lida H, Tsukagoshi S, Sakurai, Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730-3.
6. Chauffert B, Rey D, Coudert B, Dumas M, Martin F. Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumor cells. Br J Cancer 1987; 56: 119-22.
7. Yang CH, Depinho SG, Greenberger LM, Arceci RJ, Horowitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells in the endometrium of gravid uterus. J Biol Chem 1989; 264: 782-8.
8. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia by tamoxifen and other triparanol analogues. Cancer Res 1984; 44: 4392-5.
9. Rass HJ, Canada AL, Slater LM. Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers. Clin Cancer Res 1997; 3: 57-62.
10. Benson AB, Trump DL, Koeller JM, Egorin MI, Olman FA, Wine RS. Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 1985; 69: 781-95.
11. Gottesman MM, Pastan I. Clinical trials of agents that reverse multidrug-resistance. J Clin Oncol 1989; 7: 409-11.
12. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641-7.
13. Tew KD, Houghton PJ, Houghton JA. Modulation of P-glycoprotein-mediated multidrug resistance. In: Hollinger MA, ed. Preclinical and clinical modulation of anti-cancer drugs. Boca Raton, FL: CRC Press 1993: 125-97
14. Lee J, Paull K, Alvarez M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994; 46: 627-38.
15. Speicher LA, Barone LR, Chapman AE, et al. P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine. J Natl Cancer Inst 1994; 86: 688-94.
16. Choi SU, Kim NY, Choi EJ, Kim KH, Lee CO. Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch Pharm Res 1996; 19: 342-7.
17. Iwahashi T, Okochi E, Ono K, Sugawara I, Tsuruo T. Mori S. Establishment of multidrug resistant human colorectal carcinoma HCT-15 cell lines and their properties. Anti-cancer Res 1991; 11: 1309-12.
18. Manfredi JJ, Parnes J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982; 94: 688.
19. Zumino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anti-Cancer Drug, Des 1990; 5: 30-52.